Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
News Release Digital Asset Direct

Bloomsbury Publishing says latest Rundell book a work of "astonishing excellence"

Bloomsbury Publishing PLC

Bloomsbury Publishing PLC (LSE:BMY) Group Finance Director Penny Scott-Bayfield speaks to Thomas Warner from Proactive following the launch in the first of a new trilogy of books, for which Bloomsbury has exceptionally high hopes. Katherine Rundell's new book "Impossible Creatures" was released on 14 September and Scott-Bayfield describes its as a work of "astonishing excellence" and "an extraordinary book about a boy who enters this absolutely magical world and there's an element of danger and love and loss and extraordinary excitement and extraordinary originality." She highlights Rundell's track record of delivering much-loved and successful stories, noting that Rundell's work has already garnered critical acclaim, including the prestigious Costa Prize. Bloomsbury is known for being the publisher of the Harry Potter books, and Scott-Bayfield says that the company's broader strategy focuses on nurturing remarkable authors. "Part of our strategy is to develop amazing authors coming through, and we [also] benefit hugely from the success of Sarah J. Maas" whose upcoming release is highly anticipated. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 03:00 AM Eastern Daylight Time

Video

First Human Clinical Trials Of A Potentially “Game-Changing Broad Spectrum Antiviral” Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses

Benzinga

By Rachael Green, Benzinga As COVID cases begin to rise again, heralding the beginning of another COVID wave, new variants have appeared leading this wave. EG.5 (“Eris”) is currently in the majority in the U.S.A, but a very different variant, BA.2.86 (“Pirola”) is already rising in the number of cases. BA.2.86 carries more than 30 changes in its spike protein, as well as changes in other proteins. Scientists believe it is questionable whether the newest booster vaccine shots would be effective for this one. The newest vaccines are “single-agent” targeting the XBB variant. It is not known how effective the approved drugs (mainly Paxlovid - Pfizer Inc. (NYSE: PFE)) would be against this new variant, and further on, as the virus keeps changing. It is now clear that the SARS-CoV-2 virus is here to stay, and that it will keep changing as it continues to learn to avoid vaccines and antibodies and our own immune systems and continues to learn to resist existing old-fashioned drugs. Even without new variants, for clinically vulnerable patients COVID has always continued to be a terrifying reality. In light of this, the broad-spectrum antiviral that is based on a novel nanomedicines platform being developed by one emerging drug company could be promising. NanoViricides, Inc (NYSE American: NNVC ) announced that it has made progress on its Phase 1a/1b clinical trial of NV-CoV-2, a novel antiviral drug candidate that has the potential to treat all strains of the coronavirus. The clinical-stage biotech reported that the safety and tolerability parts of the trial testing the antiviral in healthy subjects is nearly complete and it’s now preparing for the efficacy and dose optimization part of the trial with COVID patients. NanoViricides Broad Spectrum Antiviral Could Change How We Treat Viral Infections So far, NanoViricides has built a robust foundation of promising preclinical research that demonstrates the unique antiviral platform’s potential to treat not just COVID-19 but a wide range of other common and hard-to-treat viral diseases like other coronaviruses, RSV, shingles, herpes, rabies and the flu. The reason it could have such broad applicability is because the NanoViricides platform was specifically designed to target a particular binding site that’s common across many viruses and doesn’t change even as a virus mutates. Essentially, the nanoviricide platform mimics the binding site on a human cell that a virus would normally target in order to infect that cell. Then it seeks out the virus and when the virus binds to the nanoviricide instead, the drug candidate immediately engulfs the virus, where it’s unable to infect the patient’s cells or reproduce. The First Of These Drugs Is Now In Human Phase 1a And 1b Clinical Trials The Phase 1a/1b clinical trial includes single-ascending dose (SAD) and multiple-ascending dose (MAD) safety and tolerability studies in healthy subjects. NanoViricides reported that 26 of the 36 volunteers in the SAD study and 17 of the 36 volunteers in the MAD study have already completed the program. And so far, the early data looks promising. Neither adverse events nor serious adverse events have been found to date in either study. "The excellent safety and tolerability of NV-CoV-2 in both formulations in the clinical trials is consistent with the results of pre-clinical animal studies, giving us confidence that our preclinical animal studies can be expected to be predictive of human clinical trials,” said NanoViricides Executive Chairman and President, Anil R. Diwan, Ph.D. Ongoing Phase 1a And 1b Clinical Trials Will Give First Indication Of Nanoviricides Efficacy In Humans With that baseline of safety and tolerability, the next part of the trial is to enroll COVID patients in the trial and start evaluating whether the positive preclinical effectiveness results for the drug will translate to human trials. Once this trial is finished, NanoViricides plans to seek permission to move into phase 2 clinical trials from multiple regulatory agencies worldwide. Of note, the same drug was found to be effective in pre-clinical studies against another important respiratory virus, RSV. Such a broad spectrum antiviral effectiveness is reminiscent of the development of antibiotics against bacteria. This could be a game-changing development in antiviral therapeutics. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2023 09:25 AM Eastern Daylight Time

B2B Video Visibility & Monetization Platform VideoXRM’s Beta Launch Surpasses 5,000 Video Uploads; Expands Content Sourcing and Audience Engagement with Launch of “Company Advocate”

VideoXRM

VideoXRM, the pioneering B2B video platform that utilizes precise subject indexing and granular search capabilities to drive greater return on investment from video assets, announced today that its Beta launch has surpassed 5,000 video uploads to its platform from a growing base of companies. VideoXRM also announced the launch of its “Company Advocate” functionality to accelerate the growth of its video library through expanded audience engagement. There is no cost to upload or search for content on VideoXRM. The VideoXRM platform provides 75 search parameters including 25 different video/audio characteristics to identify and index the unique attributes of each video, including subject, industry, specialty, participants, roles, geography, corporate status, management, etc. “Company Advocate” VideoXRM’s new “Company Advocate” functionality enables business content creators, customers, partners, media outlets or fans to upload content on behalf of a company. This new feature is designed to expand the reach, engagement, and growth of content on the VideoXRM platform. David Baker, VideoXRM’s Founder and CEO, commented, “We are excited by the growing engagement and constructive customer comments and suggestions we have gained through our Beta launch. This feedback loop has already contributed to new features such as the ‘Company Advocate’ functionality that substantially expands potential content sources and value for our platform.” VideoXRM brings the “X factor” to Customer Relationship Management (CRM) by expanding it ALL stakeholders including partners, constituents, employees, analysts, suppliers, researchers, recruiters, marketers, journalists, investors, citizens, bankers, etc. Given the growing user preference for video and rich media, VideoXRM provides a powerful new medium for exposure and precise searches. About VideoXRM ( VideoXRM.com ) VideoXRM is a global, searchable video and audio sharing and networking platform connecting corporate rich media content with all potential stakeholders. The platform and smart search technology creates value and knowledge from mountains of unstructured digital media, delivering greater ROI from content investments. VideoXRMâs mission is harnessing the enhanced communicative power of rich media through a new distribution and discovery paradigm. VideoXRM was Co-founded by David N. Baker, who formed Revere Data LLC (Sectorbase) which was acquired by FactSet Data Systems, Inc. His Co-founders are Vadim A. Tarasov, Byron Kwok, and David Guzy. Connect with us on LinkedIn and Twitter and Facebook. Contact Details Catalyst IR David C. Collins +1 212-924-9800 videoxrm@catalyst-ir.com Company Website https://videoxrm.com

September 19, 2023 08:55 AM Eastern Daylight Time

September is Cholesterol Education Month

YourUpdateTV

September is Cholesterol Education Month and for people with unsafe levels of high LDL (bad) cholesterol, there are many options in the treatment toolbox. Recently, Preventive Cardiologist Dr. Seth Baum participated in a nationwide satellite media tour to discuss high LDL cholesterol, best treatment options, and tips for patients navigating challenges with their health coverage. A video accompanying this announcement is available at: https://youtu.be/rcUk4OWkpD4 Heart disease remains the leading cause of death in the United States and LDL-cholesterol, what we call the “bad” cholesterol, is a major risk factor which can lead to a heart attack or a stroke. While many can lower their LDL cholesterol with a heart healthy diet, some will need medication to reach their Safe Zone. Statins are often the first-line of treatment for individuals with high LDL cholesterol, not all patients reach their recommended LDL cholesterol levels with statins alone. In these cases, lipid-lowering medications, known as PCSK9 inhibitors, are often recommended to help lower cholesterol levels. Unfortunately, individuals who are prescribed PCSK9 inhibitors are facing significant hurdles in accessing and using these potentially life-saving drugs, despite their proven efficacy in reducing LDL cholesterol. One major obstacle is insurance company denials or rejections. Data published in the November 2022 Journal of the American Medical Association found that for commercially insured patients prescribed a PCSK9 inhibitor, only 42% of initial rejections were overturned. Sadly, nearly 75% of patients rejected for a PCSK9 inhibitor ended up on no therapy, which is not a win for anyone. Research from the Family Heart Foundation shows that compared to individuals who were able to obtain their prescribed PCSK9 inhibitor, those whose prescription was rejected or abandoned experienced more heart attacks, strokes, and other cardiovascular events within 12 months. For more information and resources that can help, visit LDLSafeZone.org About Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC Dr. Seth J. Baum is Chief Scientific Officer at Flourish Research, and clinical affiliate professor of Cardiology at FAU Medical School. He actively consults in Clinical Lipidology and Cardiovascular Disease Prevention and continues to offer lipoprotein apheresis for patients in southeast and central Florida. Dr. Baum has practiced Preventive Cardiology and Clinical Lipidology since 2000. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. Dr. Baum is a past President of the American Society for Preventive Cardiology (ASPC). He currently serves on both the ASPC and Family Heart Foundation Advisory Boards. He has published over 100 peer reviewed papers and abstracts as well as two books. In 2013, he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. In 2019, Dr. Baum received Mended Hearts’ biennial Dwight Emary Harken Award. Dr. Baum is the Founder of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials. He has served as Principal Investigator in over 100 clinical trials covering a broad range of disease states. Dr. Baum is the Chief Scientific Officer of Flourish Research, a leading national clinical research company. Dr. Baum is a graduate of Columbia College and Columbia College of Physicians and Surgeons, and completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 18, 2023 10:27 AM Eastern Daylight Time

Video

News Direct Launches THE NEWS DIRECT PODCAST CHANNEL

News Direct

News Direct today announced the launch of The News Direct Podcast Channel, an innovative new product suite that harnesses the growing popularity and messaging impact of podcasts while leveraging the substantial SEO power of the newsdirect.com site. The News Direct Podcast Channel offers two distinct products. The first is News Directly with Steve Hutt, News Direct’s proprietary paid podcast series that provides senior corporate executives and key communications industry figures one-on-one interview opportunities with the program’s host, Steve Hutt. Hutt is the founder and host of the highly successful eCommerce Fastlane podcast who has also become a thought leader for eCommerce entrepreneurs and DTC marketing professionals. The second, and equally groundbreaking, service being launched accompanies News Directly on the channel, giving professional podcasters themselves a forum to expand their audiences. News Direct will host the programs of successful podcasting luminaries from a broad spectrum of interest areas alongside its own programming, thereby providing the benefit of newsdirect.com ’s strong domain authority to help these vehicles attract ever larger numbers of listeners and viewers. To support this effort, included in the offering will be a news release announcing each upcoming episode as well as a blog post summarizing the highlights of each interview on the site after it has been published. The company’s inaugural podcasting partners include Angelo Robles, host of Family Office TV, Ellis Martin, host of The Ellis Martin Report and News Direct partner Steve Hutt and his eCommerce Fastlane show. “The News Direct Podcast Channel is another disruptive concept we’re rolling out to advance the objective of establishing News Direct as a modern, multi-tiered message amplification platform for PR, IR and Marketing professionals”, stated Gregg Castano, founder and CEO of News Direct. “Though beginning life as an ultramodern, tech-centric newswire, we have always envisioned using that technology to become much more. With the numerous advancements of our newswire platform, we’re successfully competing head-on with the entrenched newswire status quo. But now, we can also provide communications pros with a more well-rounded suite of services to facilitate reaching target audiences via a variety of both ‘push’ and ‘pull’ strategies.” About News Direct News Direct is a technology-driven content distribution and amplification platform for PR, IR, corporate communications and marketing professionals. Our automated platform delivers a completely reimagined, modernized user experience for newswire users that has reshaped the industry landscape. Additionally, the company has expanded its offerings to include an array of technology- enhanced message amplification tools ranging from sponsored content to podcasting products, all in one online location. Contact Details News Direct Corp. News Direct Media Relations media@newsdirect.com Company Website http://www.newsdirect.com

September 18, 2023 09:00 AM Eastern Daylight Time

Image

News Release

Dog Law Specialists Cooper & Co Issue Statement on UK Government Intention to Ban American XL Bully Breed

Cooper & Co

Doglaw specialist solicitor Trevor Cooper from Cooper & Co Solicitors in Whitfield, Dover, who has acted for dog owners since the 1990s ( www.doglaw.co.uk ) today expressed his dismay that the Government has announced its intention to ban the American XL Bully under the Dangerous Dogs Act 1991 by the end of the year. “The government needs to learn from the mistakes of history, not repeat them,” said Mr Cooper. “Breed Specific Legislation has not worked. Just adding another type of dog onto the list of banned breeds is not going to protect the public. The Government needs to learn from the mistakes of history, not repeat them”. He continued “Not every XL Bully is going to be dangerous and not every owner who has one is irresponsible. If the ban is introduced, I urge the Government to have an exemption scheme which will allow dogs that do not pose a danger to public safety to be exempted from the prohibition”. “I shall need to consider the draft legislation and, in particular, will want to see how the Government is proposing to define which dogs this proposed ban applies to”. ENDS Notes Trevor Cooper is the Principal of Cooper & Co Solicitors of Whitfield, nr Dover (SRA 258139) and he maintains the website www.doglaw.co.uk. He has been qualified as a Solicitor for 36 years and is widely regarded as a leading expert in the law on dogs who deals with both civil and criminal issues on dogs in England & Wales. He can be reached on 01304 755 557 or 07768 105687 or trevor@doglaw.co.uk. Contact Details Cooper & Co Trevor Cooper +44 1304 755557 trevor@doglaw.co.uk Company Website https://doglaw.co.uk/

September 15, 2023 12:25 PM Eastern Daylight Time

Pivot To Agri-Food Sector Pays Off For Sadot Group, Inc As Company Reports First Profitable Quarter In Q2 2023

Benzinga

By Rachael Green, Benzinga In November of last year, Sadot Group Inc (NASDAQ: SDOT) pivoted from being primarily a restaurant and food service brand to becoming a global agri-food supply chain operator, sourcing agricultural products from producing regions and delivering them to markets around the world. Nine months later, it marked its ninth consecutive month of generating at least $45 million in monthly revenue. And in its second-quarter earnings released in August, it reported its first profitable quarter in its history, with quarterly revenue rising to $160 million. How Sadot Group Pivoted From Food Service To Global Agri-Food Supply Chain In November 2022, the company formerly known as Muscle Maker, Inc. formed Sadot LLC, marking the official strategic pivot into the global agri-foods supply chain sector. Since then, the company’s focus has been on becoming a leader in providing sustainable solutions that address food security issues around the world. “By broadening our perspective, we seized the opportunity to venture into new markets and businesses within the global food industry. This move not only offers significant financial prospects but also generates social and environmental value," said Sadot Group Inc. CEO Michael Roper. Its trading operations, housed under Sadot Agri-Foods, source food and feed products like soy, wheat and corn from key producing regions and deliver them to buyers across Central & South America, Asia, Africa and the Middle East. As this vertical grows, the company also plans to add logistics and transportation services as well as carbon monitoring and carbon credits. Its farm operations, housed under Sadot Farm Operations, take it a step further and actually produce those major food crops along with high-value crops like mango and avocado at the company’s farms in southern Africa. At the end of August, it added over 4,900 acre s of farmland in Zambia to its operations. The acquired farmland has the potential to harvest over 1,300 acres of corn, 775 acres of soybean, 270 acres of wheat, 180 acres of avocado and 50 acres of mango. Its first wheat harvest as Sadot-owned farmland is expected this month or early October. While its trading and farm operations mark the biggest changes and the biggest drivers of the company’s recent transition into profitability, Sadot Group hasn’t completely abandoned the food service sector where it got its start. Instead, the Company began a significant overhaul of its operations and structure to cut costs and improve revenue. That includes re-franchising the company-owned Pokémoto and Muscle Maker Grill locations, while exploring strategic options for Superfit Foods. There are currently 34 Pok é moto locations, 10 company-owned units plus 24 franchises. For Muscle Maker Grill, there are 3 company-owned locations plus an additional 10 franchised locations. The Company will focus on franchising its successful Pok é moto concept as a way to generate royalties from the brand while maintaining an asset-light business model with lower operating expenses. It has since sold 57 new franchise agreements that are expected to open in the near future. “These actions will allow us to strengthen our balance sheet and reallocate funds towards growing the agri-foods supply chain business, reinforcing our commitment to increasing shareholder value by focusing on our path to profitability, market diversification, and a strengthened brand presence," said Roper. The Multi-Million Dollar Success Of Sadot Group’s Revamped Business Strategy In the second quarter of 2022, before the formation of Sadot LLC, Muscle Maker Inc. reported a net loss of $1.8 million. One year later, Sadot Group completely flipped the script, reporting a net income of $190,000 for its second quarter of 2023. While cutting operating costs and overhead has been key, that transition into profitability was largely driven by record revenue growth coming from the company’s new trading and farming operations. Its quarterly earnings grew from $3 million in Q2 2022 to $160 million in Q2 2023, and nearly all of that came from its agri-food vertical which completed 21 transactions for the quarter, averaging $7.5 million each. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 15, 2023 09:15 AM Eastern Daylight Time

How FiscalNote (NYSE: NOTE) Is Empowering AI Integration For Governing Bodies Around The World

Benzinga

By Jad Malaeb, Benzinga FiscalNote Holdings (NYSE: NOTE) is a leader in policy and global intelligence. By uniquely combining data, technology and insights, FiscalNote uses AI to empower customers with critical insights and the tools to turn them into action. The company bolsters its leadership in the public sector arena through strategic expansions that enrich its leadership team and amplify its global coverage, and empower AI integration for governing bodies around the world. This strategic approach signifies FiscalNote's continued commitment to providing holistic solutions for traversing intricate regulatory terrains. At the core of this expansion lies FiscalNote's fortified global public sector leadership team. This augmented team amalgamates diverse expertise and a truly worldwide perspective, thereby positioning the company to proffer tailored regulatory insights and intelligence to clients across the globe. Significantly, FiscalNote has forged a partnership with the World Health Organization (WHO), attesting to the company’s acumen in delivering critical regulatory insights. This collaboration underscores FiscalNote's dedication to contributing significantly to global public health initiatives. Further amplifying FiscalNote's dedication to excellence, several distinguished organizations have become recent clients: Embassy of Japan in the U.S. Embassy of Canada in the U.S. Embassy of Pakistan in the U.S. Ministry of Unification, Korea Ministry of Economy, Trade and Industry, Japan Ministry of Foreign Affairs, United Arab Emirates Armed Forces, Sweden Europe Office (EU), Finland A national parliament in the APAC region One of the company’s most significant recently-announced partnerships has been with Korea’s Ministry of Foreign Affairs, which agreed to collaborate on the use of FiscalNote’s proprietary data sets and enhanced AI capabilities to assist the Ministry with responding to shifts in domestic and international policy. Josh Resnik, FiscalNote’s President and COO, said of the company’s global expansion focus, “Elected leaders, civil servants, diplomats, and governmental staff at all levels grapple with a tremendous amount of uncertainty, complexity, and volatility in every corner of the globe as they face an ever-growing set of policy challenges. FiscalNote continues to distinguish itself by serving as an essential, reliable, and critical partner to world’s most important decision makers who depend on our portfolio of AI solutions to deliver results.” This announcement is one of the many FiscalNote has issued demonstrating its public sector growth. Since the first quarter of 2023, FiscalNote has signed global media and healthcare companies, global commercial companies and trade associations/NGOs into their long list of partners. For an exhaustive overview of FiscalNote's strategic expansion initiatives and its esteemed partnerships, including collaborations with the World Health Organization and embassies, refer to the original press release available here. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 15, 2023 09:15 AM Eastern Daylight Time

FTN Network Acquires DFSForecast, Signs Partnership with One Week Season

FTN Network

FTN Network, a company built for delivering affordable, customizable, and highly detailed and advanced NFL data for betting, season-long fantasy, and daily fantasy, announced today that it has acquired DFSForecast, known for its Daily Fantasy Sports Lineup Builders and Advanced Data Tools. Leveraging the acquisition, FTN will provide the Optimizer to The Fantasy Footballers, and recently solidified a partnership with One Week Season to offer the DFS Optimizer to its collective userbase. Subscribers on FTNDaily.com will now be able to take advantage of DFSForecast’s lineup optimizer to create countless daily fantasy lineups in a simple and easy-to-use tool powered by FTN Data. Generated lineups can then be uploaded to one’s preferred fantasy operator, simplifying mass roster inputting. The Fantasy Footballers and One Week Season will be the first partners to use this newly acquired tool that is now part of the suite of products offered to FTN Data customers. Offered at a competitive price point compared to its competitors, FTN will look to expand its network of partners by offering this tool to those that have previously been hindered by the cost. “The 2023 football season is still very young, but FTN has seen an explosion of growth,” said FTN Network CEO Kevin Adams. “We were really impressed with the work Caleb Nelson, Sam Vitello, Adam Lewis, and the entire DFSForecast team were doing. The acquisition and incorporation of DFSForecast into our umbrella of tools offered to our customers is just another step in the journey of cementing FTN Network as the one-stop-shop for anyone when it comes to fantasy enthusiast or bettor.” "From our first meeting on, we saw FTN as a natural partner and are thrilled it's now official,” said DFSForecast Co-Founder and CEO Caleb Nelson. “We share the same data-driven approach to fantasy sports and betting. We can't wait to see how our tools add to FTN's already incredible ecosystem.” This acquisition is just one part of the burst of growth FTN Network has seen in 2023. Before the start of the 2023 football season, FTN Network announced it has signed Aaron Schatz, referred to as the founding father of football analytics, to a multi-year contract after partnering for his 2023 Football Almanac. FTN also launched “The Fantasy Football Show” on Sirius XMRadio earlier this year and has seen an incredible increase of web traffic across its network of sites. About FTN Network FTN Network is a data and entertainment network for fantasy sports and betting. Founded in 2020, FTN Network’s family of sites include Fantasy, Daily Fantasy (DFS), Betting and Data. The company has over 50 content contributors to serve the fantasy sports and betting needs of fans across key sports, including NFL, NBA, MLB, NHL, PGA, eSports, Racing and more. https://www.ftnbets.comAbout TechstarsThe Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas — entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations and cities to help build thriving startup communities. Techstars has invested in more than 2,500 companies with a combined market cap of more than $220B. https://www.techstars.com About DFSForecast DFSForecast is a leading player in the fantasy sports world, known for its Daily Fantasy Sports (DFS) Lineup Builders and Advanced Data Tools. Founded in 2018, DFSForecast uses a unique methodology that uses the characteristics of previous Milly Maker winners to build innovative, customizable and easy-to-use tools for fantasy sports players of all levels. DFSForecast is led by the trio of Caleb Nelson, Sam Vitello and Adam Lewis. Contact Details Sterling A. Randle +1 801-319-6153 srandle@hotpaperlantern.com

September 14, 2023 09:03 AM Eastern Daylight Time

1 ... 80 81 82 83 84 ... 345